Low impact
Novo Nordisk raises 2026 full-year guidance for the second time, narrowing expected sales and profit decline to 0% to -6% from prior -12% to 0%, citing stronger GLP-1 diabetes and obesity drug sales.
Jin1008/04, 11:59 PM
Novo Nordisk raises 2026 full-year guidance for the second time, projecting adjusted sales and operating profit decline of 0% to -6% at constant exchange rates, driven by higher GLP-1 drug sales; Q2 adjusted operating profit was DKK 33.39 billion.
Related assets
Coming up for NVO
Explore next
Latest NVO news
MarketWatch08/27, 03:37 PM
Deutsche Bank downgraded Novo Nordisk to sell after the stock fell 70% from its peak.
Jin1008/27, 10:33 AM
Novo Nordisk has applied for approval of an oral formulation of Wegovy for weight management.
Finnhub08/19, 05:10 PM